Structure of Azilsartan medoxomil
CAS No.: 863031-21-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Azilsartan Medoxomil is an orally available angiotensin II type 1 (AT1) receptor antagonist with IC50 value of 2.6 nM.
Synonyms: TAK-491
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 863031-21-4 |
Formula : | C30H24N4O8 |
M.W : | 568.53 |
SMILES Code : | O=C(C1=C2N(CC3=CC=C(C4=CC=CC=C4C(N5)=NOC5=O)C=C3)C(OCC)=NC2=CC=C1)OCC6=C(C)OC(O6)=O |
Synonyms : |
TAK-491
|
MDL No. : | MFCD19443688 |
InChI Key : | QJFSABGVXDWMIW-UHFFFAOYSA-N |
Pubchem ID : | 135409642 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01715584 | Hypertension | Phase 4 | Recruiting | December 31, 2019 | Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD 519 685 8500 ext 58525 Craig.Railton@lhsc.on.ca Principal Investigator: Craig J Railton, MD, PhD Sub-Investigator: Jonathan Fairbairn, BSc Sub-Investigator: George Nicoloau, MD Sub-Investigator: Robert Gros, PhD Sub-Investigator: Jason Franklin, MD Sub-Investigator: John Yoo, MD Sub-Investigator: Kevin Fung, MD Sub-Investigator: Anthony Nichols, MD Sub-Investigator: Danielle McNeil, MD Less << |
NCT02235909 | Hypertension | Phase 3 | Recruiting | August 2020 | - |
NCT00762736 | Diabetes Mellitus | Phase 2 | Completed | - | - |
NCT00376181 | Type 2 Diabetes | Phase 3 | Terminated(Combination formula... More >>tion concerns) Less << | - | - |
NCT02100319 | - | Completed | - | Japan ... More >> Osaka, Japan Tokyo, Japan Less << | |
NCT01289132 | Essential Hypertension | Phase 2 | Completed | - | - |
NCT01124656 | Diabetes Mellitus, Type 2 | Phase 3 | Terminated(Formulation issues.... More >>) Less << | - | - |
NCT03006796 | - | Recruiting | June 2019 | Russian Federation ... More >> City Hospital №5 Recruiting Moscow, Russian Federation, 107015 Contact: Elena Y Shupenina, PhD +74992684459 Less << | |
NCT01985152 | Health | Phase 1 | Unknown | - | China ... More >> TEDA International Cardiovascular Hospital Recruiting Tianjin, China Contact: Jie Hou, Associate Chief Physician 86-022-65209939 Principal Investigator: Jie Hou, Associate Chief Physician Less << |
NCT01609959 | Hypertension | Phase 4 | Completed | - | Japan ... More >> First Department of Nara Medical University Kashihara, Nara, Japan, 634-8522 Less << |
NCT00362115 | - | Completed | - | - | |
NCT00759551 | Hypertension | Phase 2 | Completed | - | - |
NCT02079805 | Essential Hypertension Complic... More >>ated by Type 2 Diabetes Mellitus Less << | Phase 4 | Completed | - | Japan ... More >> Kyoto-Shi, Kyoto, Japan Less << |
NCT02079805 | - | Completed | - | - | |
NCT00847626 | Hypertension | Phase 3 | Completed | - | - |
NCT02181816 | - | Completed | - | Japan ... More >> Osaka, Japan Tokyo, Japan Less << | |
NCT00362115 | Hypertension | Phase 2 | Completed | - | - |
NCT00847626 | - | Completed | - | - | |
NCT00696436 | Hypertension | Phase 3 | Completed | - | - |
NCT02407210 | Essential Hypertension | Phase 3 | Unknown | - | China ... More >> Beijing ANZHEN Hospital Recruiting Beijing, China, 100029 Contact: Changsheng Ma, Professor 86-010-64456078 chshma@vip.sina.com Principal Investigator: Changsheng Ma, Professor Less << |
NCT02786082 | Hypertension | Phase 1 | Completed | - | - |
NCT02609490 | Hypertension | Phase 3 | Completed | - | China ... More >> Peking University First hospiatl Beijing, China, 100000 Less << |
NCT01762501 | - | Completed | - | - | |
NCT02072330 | Grade I or II Essential Hypert... More >>ension Less << | Phase 2 Phase 3 | Completed | - | Japan ... More >> Touon-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Hanamaki-shi, Iwate, Japan Morioka-shi, Iwate, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Shinjuku-ku, Tokyo, Japan Toyama-shi, Toyama, Japan Less << |
NCT01762501 | Hypertension | Not Applicable | Completed | - | - |
NCT02348658 | Hypertension | Phase 1 | Completed | - | Japan ... More >> Fukuoka-shi, Fukuoka, Japan Less << |
NCT00696241 | Hypertension | Phase 3 | Completed | - | - |
NCT02401464 | - | Completed | - | - | |
NCT02277691 | Essential Hypertension | Phase 3 | Completed | - | Japan ... More >> Nagoya-shi, Aichi, Japan Chiba-shi, Chiba, Japan Itojima-shi, Fukuoka, Japan Kouriyama-shi, Fukushima, Japan Sapporo-shi, Hokkaido, Japan Amagasaki-shi, Hyougo, Japan Tsukuba-shi, Ibaragi, Japan Morioka-shi, Iwate, Japan Sakaide-shi, Kagawa, Japan Takamatsu-shi, Kagawa, Japan Kawasaki-shi, Kanagawa, Japan Kyoto-shi, Kyoto, Japan Uji-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Hirakata-shi, Osaka, Japan Osaka-shi, Osaka, Japan Takatsuki-shi, Osaka, Japan Saitama-shi, Saitama, Japan Tokorozawa-shi, Saitama, Japan Yaizu-shi, Shizuoka, Japan Chiyoda-ku, Tokyo, Japan Choufu-shi, Tokyo, Japan Kodaira-shi, Tokyo, Japan Koutou-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Choufu-shi, Japan Kawasaki-shi, Japan Koutou-ku, Japan Morioka-shi, Japan Sakaide-shi, Japan Setagaya-ku, Japan Shinagawa-ku, Japan Shinjuku-ku, Japan Tsukuba-shi, Japan Uji-shi, Japan Yaizu-shi, Japan Less << |
NCT00696436 | - | Completed | - | - | |
NCT02277691 | - | Completed | - | - | |
NCT02092025 | - | Completed | - | Japan ... More >> Osaka, Japan Tokyo, Japan Less << | |
NCT02348658 | - | Completed | - | - | |
NCT00696241 | - | Completed | - | - | |
NCT02401464 | Japanese Healthy Adult Males | Phase 1 | Completed | - | Japan ... More >> Kagoshima, Japan Less << |
NCT00591266 | Hypertension | Phase 3 | Completed | - | - |
NCT00591773 | Hypertension | Phase 3 | Completed | - | - |
NCT00591266 | - | Completed | - | - | |
NCT00591773 | - | Completed | - | - | |
NCT00760214 | Hypertension | Phase 3 | Completed | - | - |
NCT00760214 | - | Completed | - | - | |
NCT00696384 | Hypertension | Phase 3 | Completed | - | - |
NCT01078376 | - | Terminated(Business Decision (... More >>see below)) Less << | - | - | |
NCT00696384 | - | Completed | - | - | |
NCT00591253 | Hypertension | Phase 3 | Completed | - | - |
NCT00846365 | Essential Hypertension | Phase 3 | Completed | - | - |
NCT01078376 | Hypertension | Phase 1 | Terminated(Business Decision (... More >>see below)) Less << | - | United States, Arkansas ... More >> Little Rock, Arkansas, United States United States, Georgia Atlanta, Georgia, United States United States, Kentucky Louisville, Kentucky, United States United States, Ohio Toledo, Ohio, United States United Kingdom Birmingham, England, United Kingdom Bristol, England, United Kingdom London, England, United Kingdom Manchester, England, United Kingdom Less << |
NCT00591578 | Hypertension | Phase 3 | Completed | - | - |
NCT00591578 | - | Completed | - | - | |
NCT01033071 | Essential Hypertension | Phase 3 | Completed | - | - |
NCT00591253 | - | Completed | - | - | |
NCT00996281 | Essential Hypertension | Phase 3 | Completed | - | Austria ... More >> Graz, Styria, Austria Germany Karlsruhe, Baden-Wurttemberg, Germany Hannover, Lower Saxony, Germany Kiel-Kronshagen, Schleswig-Holstein, Germany Netherlands Breda, North Brabant, Netherlands Eindhoven, North Brabant, Netherlands Amsterdam, North Holland, Netherlands Velp, Rheden, Netherlands Leiderdorp, South Holland, Netherlands Zoetermeer, South Holland, Netherlands Rotterdam, Zuid-Holland, Netherlands Groningen, Netherlands Poland Bydgoszcz, Kuyavian-Pomeranian, Poland Skierniewice, L0dz, Poland Zgierz, L0dz, Poland Gdansk, Pomeranian, Poland Gdynia, Pomeranian, Poland Sopot, Pomeranian, Poland Mikolow, Silesian, Poland United Kingdom Avon, England, United Kingdom Bolton, England, United Kingdom Chorley, England, United Kingdom Inverness, England, United Kingdom Liverpool, England, United Kingdom Surrey, England, United Kingdom Warwickshire, England, United Kingdom Less << |
NCT01033071 | - | Completed | - | - | |
NCT00846365 | - | Completed | - | - | |
NCT03434977 | Healthy Adult Male Participant... More >>s Less << | Phase 1 | Completed | - | Japan ... More >> Fukuoka Mirai Hospital Fukuoka, Japan Less << |
NCT00996281 | - | Completed | - | - | |
NCT01309828 | - | Completed | - | - | |
NCT00695955 | Hypertension | Phase 3 | Completed | - | - |
NCT02400775 | Essential Hypertension With St... More >>able Angina and Dyslipidemia Less << | Phase 4 | Withdrawn | - | Japan ... More >> Tokushima, Japan Less << |
NCT00695955 | - | Completed | - | - | |
NCT01309828 | Safety | Phase 3 | Completed | - | - |
NCT01496430 | Hypertension ... More >>Diabetes Less << | Phase 3 | Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << | - | - |
NCT01774591 | Hypertension | Not Applicable | Completed | - | United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less << |
NCT01774591 | - | Completed | - | - | |
NCT00818883 | Essential Hypertension | Phase 3 | Completed | - | - |
NCT03652792 | Bioequivalence of Two Azilsart... More >>an Formulations Less << | Phase 1 | Completed | - | Hong Kong ... More >> Phase I Clinical Trial Centre, Chinese University of Hong Kong Hong Kong, Sha Tin New Territories, Hong Kong, 000000 Less << |
NCT00818883 | - | Completed | - | - | |
NCT03042299 | Japanese Healthy Adult Male Pa... More >>rticipants Less << | Phase 1 | Completed | - | Japan ... More >> Nishi Kumamoto Hospital Kumamoto, Japan Less << |
NCT02791438 | Pediatric Hypertension | Phase 3 | Active, not recruiting | June 11, 2019 | Japan ... More >> Nagakute, Aichi, Japan Nagoya, Aichi, Japan Obu, Aichi, Japan Sapporo, Hokkaido, Japan Kobe, Hyogo, Japan Kanazawa, Ishikawa, Japan Yokohama, Kanagawa, Japan Nankoku, Kochi, Japan Sendai, Miyagi, Japan Shimajiri-gun, Okinawa, Japan Izumi, Osaka, Japan Osaka Sayama, Osaka, Japan Otsu, Shiga, Japan Shimotsuke, Tochigi, Japan Fuchu, Tokyo, Japan Nerima-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Akita, Japan Chiba, Japan Fukuoka, Japan Fukushima, Japan Hiroshima, Japan Niigata, Japan Okayama, Japan Osaka, Japan Saitama, Japan Shizuoka, Japan Wakayama, Japan Less << |
NCT02480764 | Essential Hypertension | Phase 3 | Completed | - | - |
NCT01496430 | - | Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << | - | - | |
NCT02451150 | Pediatric Hypertension | Phase 3 | Completed | - | Japan ... More >> Fuchu, Japan Oofu, Japan Setagaya-ku, Japan Less << |
NCT03042299 | - | Completed | - | - | |
NCT02451150 | - | Completed | - | - | |
NCT01456169 | - | Completed | - | - | |
NCT02235519 | Hypertension ... More >>Obesity Type 2 Diabetes Mellitus Less << | Phase 2 Phase 3 | Unknown | June 2015 | Mexico ... More >> Hospital General de Mexico "Dr. Eduardo Liceaga" Recruiting Mexico, Mexico, D.F., Mexico, 06720 Contact: Juan A Peralta, bachelor Less << |
NCT02541669 | Healthy Volunteer | Phase 1 | Completed | - | China, Beijing,P.R. ... More >> Beijing, Beijing,P.R., China Less << |
NCT02203916 | Hypertension | Phase 3 | Completed | - | Korea, Republic of ... More >> Chuncheon-Si, Gangwon-do, Korea, Republic of Wonju-Si, Gangwon-do, Korea, Republic of Anyang-si, Gyeonggi-do, Korea, Republic of Goyang-si, Gyeonggi-do, Korea, Republic of Seongnam-si, Gyeonggi-do, Korea, Republic of Suwon-si, Gyeonggi-do, Korea, Republic of Daegu, Gyeongsangbuk-do, Korea, Republic of Yangsan-si, Gyeongsangnam-do, Korea, Republic of Jeonju-si, Jeollabuk-do, Korea, Republic of Gwangju, Jeollanam-do, Korea, Republic of Busan, Korea, Republic of Daegu, Korea, Republic of Daejeon, Korea, Republic of Incheon, Korea, Republic of Seoul, Korea, Republic of Less << |
NCT02517866 | Essential Hypertension ... More >> Type 2 Diabetes Mellitus Less << | Phase 4 | Completed | - | China, Hong Kong ... More >> Hong Kong, Hong Kong, China Taiwan Changhua county, Taiwan Kaohsiung City, Taiwan Kaohsiung, Taiwan Taichung, Taiwan Tainan City, Taiwan Taipei, Taiwan Taoyuan County, Taiwan Thailand Bangkok, Thailand Chiang Mai, Thailand Khon Kaen, Thailand Pathumtani, Thailand Less << |
NCT01456169 | Essential Hypertension | Phase 3 | Completed | - | - |
NCT02203916 | - | Completed | - | - | |
NCT03539627 | - | Not yet recruiting | June 2021 | - | |
NCT02756819 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.79mL 1.76mL 0.88mL |
17.59mL 3.52mL 1.76mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|